ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1375

The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome

Jee-in Lee1, Se Rim Choi2, You-Jung Ha2, Eun Ha Kang3, Keun-Suh Kim4, Joon Young Hyon5 and Yun Jong Lee6, 1Seoul National University of Bundang Hospital, Seongnam, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnamsi, South Korea, 3Seoul National University Bundang Hospital, Seongnam, South Korea, 4Department of Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seongnamsi, South Korea, 5Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnamsi, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), Fatigue, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate the prevalence of anti-thyroid autoantibodies, abnormal thyroid function, and their clinical impacts in Korean patients with primary Sjögren’s syndrome (pSS).

Methods: One hundred ninety-six pSS patients (190 females; median age 58.6 [IQR, 46.5-67.3]), satisfying the 2016 ACR/EULAR criteria, were consecutively enrolled. Those with a history of overt thyroid disease (n=22) or thyroid cancer (n=4) were excluded. Clinical variables including EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) and Patient Reported Index (ESSPRI) were collected. For the relative contribution of fatigue to ESSPRI, the fraction of fatigue (Ffatigue) was calculated using ESSPRI fatigue score/ESSPRI score. Laboratory data including the complete blood count, ESR, and levels of thyroid-stimulating hormone (TSH; uIU/mL), free T4 (ng/dL), IgG, β2-microglobulin, cryoglobulin, and complement C3 and C4 were assessed. TSH/fT4 ratio was calculated. Anti-thyroglobulin (TG), anti-thyroperoxidase (TPO), TSH-binding inhibiting immunoglobulin (TBII), and anti-TSH receptor antibody (TSHR) were measured. Subclinical hypothyroidism (ST) was defined as TSH > 4.0 and the presence of hypothyroidism-related autoantibodies. The Mann-Whitney test, Chi-squared or Fischer’s exact test, and logistic regression analysis were performed.

Results: Of 196 patients, 71 (36.2%) had one of the anti-thyroid autoantibodies and 53 (27%) had one of the hypothyroidism-related autoantibodies. The prevalence of anti-TG, anti-TPO, TBII, and anti-TSHR was 31 (15.8%), 28 (14.3%), 8 (4.1%), and 28 (14.3%), respectively. Twenty-four (12.2%) had TSH > 4.0 and 3 (1.5%) had TSH < 0.3. No patients had TSH > 10.0. ST was observed in 7 (3.6%) and was significantly associated with anti-TPO (p < 0.001) and TBII (p < 0.05). Patients with anti-TSHR had significantly higher levels of ESSDAI or clinical ESSDAI (both p < 0.05) and those with TSH/fT4 ≥ 4.14 had significantly higher Ffatigue levels (p < 0.01; Fig. 1). In multivariate logistic regression analyses, subclinical hypothyroidism (OR=5.61 [95% CI 1.07-29.50]) or TFI ≥ 4.14 (OR=9.01 [2.35-34.56]) was associated with the top quantile of Ffatigue. Additionally, TSH/fT4 ≥ 4.14 was an independent predictor for the highest quantile of Ffatigue (OR=8.00 [2.05-31.26]; Table 1).

Conclusion: Despite a high positive rate of thyroid-related autoantibodies, subclinical hypothyroidism was uncommonly observed in Korean pSS patients. The high TSH/fT4 ratio was significantly associated with “fatigue-dominance” in ESSPRI, and it may be related to the neuroendocrine aspects of fatigue in pSS.

Supporting image 1

Figure 1. ESSDAI (A) and clinical ESSDAI (ClinESSDAI, B) levels were significantly different according to anti-TSH receptor (TSHR) positivity. Fatigue VAS levels were compatible (C) but fractions of fatigue in ESSPRI were significantly higher in patient with TSH/fT4 ≥4.14 (D) than those with TSH/fT4 <4.14. P values were calculated by the Mann-Whitney test.

Supporting image 2

Table 1. Logistic regression analysis results for the highest quartile of the fraction of fatigue in ESSPRI. Variables with p <0.1 in univariate analyses were incorporated into the multivariate analysis.


Disclosures: J. Lee: None; S. Choi: None; Y. Ha: None; E. Kang: None; K. Kim: None; J. Hyon: None; Y. Lee: None.

To cite this abstract in AMA style:

Lee J, Choi S, Ha Y, Kang E, Kim K, Hyon J, Lee Y. The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-relative-burden-of-fatigue-is-associated-with-high-tsh-ft4-ratio-in-korean-patients-with-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relative-burden-of-fatigue-is-associated-with-high-tsh-ft4-ratio-in-korean-patients-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology